Skip to main content
KTTA
NASDAQ Life Sciences

Pasithea Therapeutics Reports Improved Q1 Net Loss, Strong Cash Position, and Increased R&D Spending

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.784
Mkt Cap
$19.456M
52W Low
$0.281
52W High
$2.06
52W Position info
179% above low
Off High info
62% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

KTTA has more than doubled off its 52-week low of $0.281.

Summary

Pasithea Therapeutics reported an improved Q1 net loss and a robust $50.4 million cash balance, providing a solid runway for its significantly increased R&D efforts, crucial for a clinical-stage biotech facing Nasdaq compliance issues.


Key Events · Earnings and Guidance · KTTA

  • Improved Net Loss

    Net loss decreased to $(2.87) million in Q1 2026 from $(3.56) million in Q1 2025.

  • Strong Cash Position

    The company holds $50.4 million in cash and equivalents as of March 31, 2026, providing over 12 months of liquidity.

  • Increased R&D Investment

    Research and development expenses rose 70.1% to $2.94 million, reflecting continued pipeline advancement.

  • Warrant Reclassification

    $2.29 million in December 2025 Placement Agent Warrants were reclassified from liability to equity following an increase in authorized shares.


Analysis · KTTA · Life Sciences

Pasithea Therapeutics, a clinical-stage biotech, reported an improved net loss for Q1 2026 and maintains a substantial cash balance of $50.4 million, which management believes is sufficient for over 12 months of operations. This strong liquidity is critical, especially following a recent Nasdaq deficiency notice. The company also significantly increased its R&D spending by 70.1%, signaling continued investment in its pipeline, including the PAS-004 program which recently received FDA Fast Track and Rare Pediatric Disease designations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KTTA was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.5M. The 52-week trading range was $0.28 to $2.06. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KTTA - Latest Insights

KTTA
Nov 17, 2026, 8:42 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $0.4343
Real-time Price: $0.465 info
Change: +$0.0307 (+7%) info
Market Cap: $17.593M info
KTTA
Nov 13, 2026, 5:17 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.479
Real-time Price: $0.465 info
Change: -$0.014 (-3%) info
Market Cap: $17.593M info
KTTA
Nov 13, 2026, 2:00 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.510
Real-time Price: $0.465 info
Change: -$0.045 (-9%) info
Market Cap: $17.593M info
KTTA
Nov 03, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.3591
Real-time Price: $0.465 info
Change: +$0.1059 (+29%) info
Market Cap: $17.593M info
KTTA
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.550
Real-time Price: $0.465 info
Change: -$0.085 (-15%) info
Market Cap: $17.593M info